SCHEMBL5952719

SCHEMBL5952719

CCC(C)OB(O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 2/20 0.40
ORAI1 Q96D31 3/20 0.38
ORAI2 Q96SN7 3/20 0.38
ORAI3 Q9BRQ5 3/20 0.38
TRPV6 Q9H1D0 3/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
ENPP2 Q13822 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
LMNA P02545 2/20 0.37
MAPT P10636 1/20 0.36
TRPA1 O75762 2/20 0.35
TSHR P16473 2/20 0.34
ABCB1 P08183 1/20 0.32
ABCC1 P33527 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5952943 0.83 LPL (0.43) ORAI1ORAI2ORAI3TRPV6
SCHEMBL1226528 0.79 TRPV6 (0.44) PCSK9ORAI1ORAI2ORAI3TRPV6
SCHEMBL4855266 0.74 LMNA (0.39) LMNAMAPTTRPA1TSHRMEN1
SCHEMBL1997852 0.74 CA1 (0.50) CA7CA14LMNAMAPTTSHR
SCHEMBL5951904 0.73 HTR1B (0.37) LMNATSHRABCB1KDM4EKMT2A
SCHEMBL1722636 0.71 PCSK9 (0.45) PCSK9ORAI1ORAI2ORAI3TRPV6
SCHEMBL15570627 0.71 TRPV6 (0.44) PCSK9ORAI1ORAI2ORAI3TRPV6
SCHEMBL28726874 0.71 LMNA (0.42) PCSK9ORAI1ORAI2ORAI3TRPV6
SCHEMBL28423595 0.71 ENPP2 (0.39) PCSK9ORAI1ORAI2ORAI3TRPV6
SCHEMBL18526870 0.71 LMNA (0.52) PCSK9ORAI1ORAI2ORAI3TRPV6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4715026-A1 BORON-CONTAINING QUANTUM DOT COMPLEX AGGREGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF Cannano Jiayuan (Guangzhou) Science & Technology Co., Ltd. (CN) 2026-03-25 EP disclosed
US-7038070-B2 Preparation of preparing substituted indanones BASELL POLYOLEFINE GMBH (DE) 2006-05-02 US disclosed
US-6963017-B2 Preparation of preparing substituted indanones BASELL POLYOLEFINE GMBH (DE) 2005-11-08 US disclosed
EP-0968158-B1 METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM BASELL POLYOLEFINE GMBH (DE) 2005-08-10 EP disclosed
US-20050033076-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2005-02-10 US disclosed
US-20030009046-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2003-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050033076-A1 Preparation of preparing substituted indanones CYP1A2, CYP2J2, IDH3A PCSK9 3742/4885ORAI1 4605/4885ORAI2 1642/4885
US-20030009046-A1 Preparation of preparing substituted indanones CYP1A2, CYP1B1, CYP1A1 PCSK9 3869/4885ORAI1 4577/4885ORAI2 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.